Hexima Limited. (ASX:HXL)
Hexima Limited is an Australia-based clinical stage biotechnology company. The Company is engaged in the research and development of defensin peptides for applications as human therapeutics. The Company’s lead product candidate, pezadeftide applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections or onychomycosis. pezadeftide is under Australian Phase IIb clinical trial. It develops for the treatment of onychomycosis. The Company holds granted, long-life patents protecting pezadeftide in markets globally.